[334] Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
[335] Enarson DA, Chretien J. Epidemiology of respiratory infectious diseases. Curr Opin Pulm Med 1999;5:128-35.
[336] Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202.
[337] Orege PA, Fine PE, Lucas SB, Obura M, Okelo C, Okuku P. Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Int J Lepr Other Mycobact Dis 1993;61:542-9.
[338] Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-8.
[339] Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.
[340] Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989;11 Suppl 2:S353-9.
[341] Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002;70:672-8.
[342] Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YA. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 2003;83:213-9.
[343] McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005;85:47-52.
[344] World Health Organization. Global Tuberculosis Control. Geneva, Switzerland; 2006.
[345] Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938-40.
[346] Smith KC, Orme IM, Starke JR. Tuberculosis vaccines. In: Plotkin SA, Orenstein WA, Offrit PA, editors. Vaccine 5th ed Saunders-Elsevier 2008: 857-85.
[347] Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 2007;196 Suppl 3:S482-90.
[348] Koenig R. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 2008;319:894-7.
[349] Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and threats. FEMS Immunol Med Microbiol 2008;53:145-50.
[350] Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008;300:431-3.
[351] Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal Wkly Rep 2007;56:250-3.
[352] Trends in tuberculosis incidence--United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:245-50.
[353] Bégué P, Denis. F, Girard MP, Frottier J. Faut-il continuer à vacciner par le BCG en France? Bull Acad Natle Med 2005;189:1305-18.
[354] Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 2004;112:461-70.
[355] Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med 2000;192:347-58.
[356] Villarreal-Ramos B, McAulay M, Chance V, Martin M, Morgan J, Howard CJ. Investigation of the role of CD8+ T cells in bovine tuberculosis in vivo. Infect Immun 2003;71:4297-303.

[357] Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, Pasvol G, et al. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994;81:171-6.
[358] Orme IM. Prospects for new vaccines against tuberculosis. Trends Microbiol 1995;3:401-4.
[359] Park JS, Tamayo MH, Gonzalez-Juarrero M, Orme IM, Ordway DJ. Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol 2006;79:80-6.
[360] Bénévolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LR. BCG Moreau Rio de Janeiro- An oral vaccine against tuberculosis-Review Mem Inst Oswaldo Cruz Rio de Janeiro 2005 100:459-65.
[361] Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007;82:193-6.
[362] Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007;25:14-8.
[363] Mak TK, Hesseling AC, Hussey GD, Cotton MF. Making BCG vaccination programmes safer in the HIV era. Lancet 2008;372:786-7.
[364] Philipp WJ, Nair S, Guglielmi G, Lagranderie M, Gicquel B, Cole ST. Physical mapping of Mycobacterium bovis BCG pasteur reveals differences from the genome map of Mycobacterium tuberculosis H37Rv and from M. bovis. Microbiology 1996;142 (Pt 11):3135-45.
[365] Mustafa AS, Cockle PJ, Shaban F, Hewinson RG, Vordermeier HM. Immunogenicity of Mycobacterium tuberculosis RD1 region gene products in infected cattle. Clin Exp Immunol 2002;130:37-42.
[366] Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J Infect Dis 2003;187:117-23.
[367] Liu XQ, Dosanjh D, Varia H, Ewer K, Cockle P, Pasvol G, et al. Evaluation of T-cell responses to novel RD1- and RD2-encoded Mycobacterium tuberculosis gene products for specific detection of human tuberculosis infection. Infect Immun 2004;72:2574-81.
[368] Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 2007;104:5596-601.
[369] Weir RE, Gorak-Stolinska P, Floyd S, Lalor MK, Stenson S, Branson K, et al. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis 2008;8:9.
[370] Brewer TF, Colditz GA. Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995;20:126-35.
[371] Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
[372] Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 2005;18:687-702.
[373] Girard MP, Fruth U, Kieny MP. A review of vaccine research and development: tuberculosis. Vaccine 2005;23:5725-31.
[374] Young D, Dye C. The development and impact of tuberculosis vaccines. Cell 2006;124:683-7.
[375] Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008;7:635-50.
[376] Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000;97:13853-8.
[377] Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005;7:947-54.
[378] Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008;198:1491-501.

[379] Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-9.
[380] Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005;115:2472-9.
[381] Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4:469-76.
[382] Abebe F, Bjune G. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guerin (BCG) vaccines: is there a link? Clin Exp Immunol 2006;145:389-97.
[383] Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR, Jr., Bloom BR. Auxotrophic vaccines for tuberculosis. Nat Med 1996;2:334-7.
[384] Collins DM. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Immunol Cell Biol 2000;78:342-8.
[385] Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006;24:3408-19.
[386] Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005;85:29-38.
[387] Sampson SL, Dascher CC, Sambandamurthy VK, Russell RG, Jacobs WR, Jr., Bloom BR, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004;72:3031-7.
[388] Rosada RS, de la Torre LG, Frantz FG, Trombone AP, Zarate-Blades CR, Fonseca DM, et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 2008;9:38.
[389] Andersen P. TB vaccines: progress and problems. Trends Immunol 2001;22:160-8.
[390] Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb) 2005;85:25-8.
[391] Hope JC, Villarreal-Ramos B. Bovine TB and the development of new vaccines. Comp Immunol Microbiol Infect Dis 2008;31:77-100.
[392] Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999;67:2941-50.
[393] Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000;68:791-5.
[394] Skeiky YA, Ovendale PJ, Jen S, Alderson MR, Dillon DC, Smith S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000;165:7140-9.
[395] Skjot RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002;70:5446-53.
[396] Alderson MR, Bement T, Day CH, Zhu L, Molesh D, Skeiky YA, et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med 2000;191:551-60.
[397] Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004;72:6148-50.
[398] Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005;23:2740-50.
[399] Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005;174:6332-9.

[400] Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004;172:7618-28.
[401] McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-4.
[402] Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. J Infect Dis 2008;198:544-52.
[403] Vordermeier HM, Simsova M, Wilkinson KA, Wilkinson RJ, Hewinson RG, Sebo P, et al. Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis. Infect Immun 2004;72:6255-61.
[404] Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2007;2:e1052.
[405] Vordermeier HM, Huygen K, Singh M, Hewinson RG, Xing Z. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect Immun 2006;74:1416-8.
[406] Sander C, McShane H. Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis. Clin Exp Immunol 2007;147:401-11.